The WACC of Eastwood Bio-Medical Canada Inc (EBM.V) is 6.5%.
Range | Selected | |
Cost of equity | 5.7% - 7.4% | 6.55% |
Tax rate | 26.2% - 27.0% | 26.6% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 5.7% - 7.4% | 6.5% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 5.1% | 6.1% |
Adjusted beta | 0.36 | 0.41 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 5.7% | 7.4% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 0 | 0 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 5.7% | 7.4% |
Selected WACC | 6.5% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
EBM.V | Eastwood Bio-Medical Canada Inc | 0 | -3.23 | -3.23 |
ALID | Allied Corp | 5.05 | -0.37 | -0.08 |
ASP.TO | Acerus Pharmaceuticals Corporation | 11.68 | 1.14 | 0.12 |
BAMM.CN | Body and Mind Inc | 4.03 | 0.18 | 0.05 |
COOL.CN | Core One Labs Inc | 0.04 | 0.14 | 0.13 |
CURR | Cure Pharmaceutical Holding Corp | 0 | -0.38 | -0.38 |
FLWR.V | Flowr Corp | 2.08 | 0.52 | 0.21 |
FONE.CN | Flower One Holdings Inc | 53.4 | 1.84 | 0.05 |
PCSA | Processa Pharmaceuticals Inc | 0 | 0.23 | 0.23 |
ROMJ.V | Rubicon Organics Inc | 0.34 | -1.1 | -0.88 |
XPHY.CN | Xphyto Therapeutics Corp | 0.09 | 1 | 0.94 |
Low | High | |
Unlevered beta | 0.05 | 0.12 |
Relevered beta | 0.04 | 0.12 |
Adjusted relevered beta | 0.36 | 0.41 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for EBM.V:
cost_of_equity (6.55%) = risk_free_rate (4.15%) + equity_risk_premium (5.60%) * adjusted_beta (0.36) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.